Shamburg News · 8-K filed Oct 29, 2026, 8:35 AM EDT
Azitra Expands ATR-04 Phase 1/2 Trial Eligibility to Include KRAS and MEK Inhibitor Rash
AZTR · Azitra, Inc.
- Other event
- Materiality: medium
Azitra, Inc. announced amendments to its Phase 1/2 clinical trial of ATR04-484 that expand patient eligibility to include individuals with rash associated with KRAS and MEK inhibitors, including patients with neurofibromatosis type 1 with MEK inhibitor-associated rash. The amendments also shorten required washout periods for antibiotics and steroids. The protocol changes follow the safety review committee's recommendation to proceed to Cohort 2, which is expected to enroll approximately 24 patients. The press release is furnished as Exhibit 99.1 to the filing dated October 29, 2026.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001493152-26-049191.
Written from the filing by Shamburg Markets. Figures are as reported by the company.